{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:36:49Z","timestamp":1790422609162,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T00:00:00Z","timestamp":1503273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.autrev.2017.07.019","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T05:31:43Z","timestamp":1501565503000},"page":"1029-1035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Role of anti-receptor autoantibodies in pathophysiology of scleroderma"],"prefix":"10.1016","volume":"16","author":[{"given":"Melvin","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia D.","family":"Steen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2017.07.019_bb0005","series-title":"Pathogenesis of systemicsclerosis (scleroderma) Up To Date","author":"Denton","year":"2016"},{"key":"10.1016\/j.autrev.2017.07.019_bb0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/ITT.S82037","article-title":"Current perspectives on the immunopathogenesis of systemic sclerosis","volume":"5","author":"Fuschiotti","year":"2016","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.autrev.2017.07.019_bb0015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.7326\/0003-4819-59-3-351","article-title":"Scleroderma of the esophagus. A correlation of histologic and physiologic findings","volume":"59","author":"Treacy","year":"1963","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.autrev.2017.07.019_bb0020","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/annrheumdis-2011-200631","article-title":"Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO registry","volume":"71","author":"Denton","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.019_bb0025","doi-asserted-by":"crossref","first-page":"R22","DOI":"10.1186\/ar2614","article-title":"Antibodies against PM\/Scl-75 and PM\/Scl-100 are independent markers for different subsets of systemic sclerosis patients","volume":"11","author":"Hanke","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"2 Suppl 76","key":"10.1016\/j.autrev.2017.07.019_bb0030","first-page":"96","article-title":"Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study","volume":"31","author":"Heijnen","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2017.07.019_bb0035","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/BOR.0000000000000113","article-title":"Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement","volume":"26","author":"Domsic","year":"2014","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2017.07.019_bb0040","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1586\/1744666X.2013.848792","article-title":"Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development","volume":"9","author":"Castelino","year":"2013","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2017.07.019_bb0045","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/art.11173","article-title":"Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance of the presence of antinuclear antibodies","volume":"48","author":"Feghali-Bostwick","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.019_bb0050","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/rheumatology\/keu155","article-title":"Epigenetics, the holy grail in the pathogenesis of systemic sclerosis","volume":"54","author":"Altorok","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"10 Pt 2","key":"10.1016\/j.autrev.2017.07.019_bb0055","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/j.lpm.2014.08.001","article-title":"Pathophysiology of systemic sclerosis: state of the art in 2014","volume":"43","author":"Dumoitier","year":"2014","journal-title":"Presse Med"},{"key":"10.1016\/j.autrev.2017.07.019_bb0060","doi-asserted-by":"crossref","first-page":"36474","DOI":"10.1074\/jbc.M502851200","article-title":"Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1\/2. Amplification of ROS andRas in systemic sclerosis fibroblasts","volume":"280","author":"Svegliati","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2017.07.019_bb0065","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1172\/JCI107084","article-title":"The pathogenesis of esophageal dysfunction in scleroderma and Raynaud's disease","volume":"51","author":"Cohen","year":"1972","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2017.07.019_bb0070","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1172\/JCI117395","article-title":"Antimyenteric neuronal antibodies in scleroderma","volume":"94","author":"Howe","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2017.07.019_bb0075","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0022-2143(99)90184-1","article-title":"Myenteric neuronal antibodies in scleroderma: passive transfer evokes alterations in intestinal myoelectric activity in a rat model","volume":"133","author":"Eaker","year":"1999","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.autrev.2017.07.019_bb0080","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1053\/gast.2002.36057","article-title":"Antibody-mediate gastrointestinal dysmotility in scleroderma","volume":"123","author":"Goldblatt","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2017.07.019_bb0085","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1002\/art.11343","article-title":"Anti-idiotypic antibodies neutralize autoantibodies that inhibit cholinergic neurotransmission","volume":"48","author":"Cavill","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.019_bb0090","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/ard.2008.096545","article-title":"Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility","volume":"68","author":"Kawaguchi","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.019_bb0095","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/cei.12324","article-title":"A novel luminescence-based method for the detection of functionally active antibodies to muscarinincacetylcholine receptors of the M3 type (mAchR3) in patients' sera","volume":"177","author":"Preuss","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2017.07.019_bb0100","doi-asserted-by":"crossref","first-page":"G1206","DOI":"10.1152\/ajpgi.00286.2009","article-title":"Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells","volume":"297","author":"Singh","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.autrev.2017.07.019_bb0105","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1053\/j.gastro.2012.07.109","article-title":"Effects of scleroderma antibodies and pooled human immunoglobulin on anal sphincter and colonic smooth muscle function","volume":"143","author":"Singh","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2017.07.019_bb0110","doi-asserted-by":"crossref","first-page":"G1052","DOI":"10.1152\/ajpgi.00034.2016","article-title":"Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG","volume":"310","author":"Kumar","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.autrev.2017.07.019_bb0115","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/rheumatology\/kev318","article-title":"Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis","volume":"55","author":"Raja","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.019_bb0120","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2249.2009.04059.x","article-title":"Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis","volume":"159","author":"Odaka","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2017.07.019_bb0125","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2249.2004.02615.x","article-title":"Autoantibiody against matrix mettaloprotease-3 in patients with systemic sclerosis","volume":"138","author":"Hishijima","year":"2004","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2017.07.019_bb0130","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3899\/jrheum.150088","article-title":"The endothelial-mesenchymal transition in systemic sclerosis is induced by endothelin-1 and transforming growth factor-\u03b2 and may be blocked by macitentan, a dual endothelin-1 receptor antagonist","volume":"42","author":"Cipriani","year":"2015","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.019_bb0135","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2017.07.019_bb0140","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1002\/art.34482","article-title":"A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis","volume":"64","author":"Steen","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.019_bb0145","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3899\/jrheum.090600","article-title":"Gastric antral vascular ectasia in systemic sclerosis: demographics and disease predictors","volume":"37","author":"Ingraham","year":"2010","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.019_bb0150","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3899\/jrheum.130386","article-title":"Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study","volume":"41","author":"Ghr\u00e9nassia","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.019_bb0155","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/762546","article-title":"Gastric antral vascular ectasia in systemic sclerosis: current concepts","author":"Parrado","year":"2015","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.019_bb0160","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","article-title":"Myasthenia gravis","volume":"330","author":"Drachman","year":"1994","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.autrev.2017.07.019_bb0165","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.07.019_bb0170","first-page":"504","article-title":"Thyrotropin receptor antibodies in hypothyroid Graves' disease","volume":"76","author":"Kasagi","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2017.07.019_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118312","article-title":"Clinical features of autoimmune autonomic ganglionopathy and the detection of subunit-specific autoantibodies to the ganglionic acetylcholine receptor in Japanese patients","volume":"10","author":"Nakane","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2017.07.019_bb0180","first-page":"1","article-title":"Ganglionic acetylcholine receptor autoantibodies in patients with autoimmune diseases including primary biliary cirrhosis","author":"Maeda","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.019_bb0185","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMe048335","article-title":"Agonistic autoantibodies and rejection of renal allografts","volume":"352","author":"Ingelfnger","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.07.019_bb0190","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/0167-5699(93)90244-F","article-title":"Defining criteria for autoimmune diseases (Witebsky's postulates revisted)","volume":"14","author":"Rose","year":"1993","journal-title":"Immunol Today"},{"issue":"10","key":"10.1016\/j.autrev.2017.07.019_bb0195","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1016\/j.bbapap.2012.10.015","article-title":"Platelet-derived growth factors and their receptors: structural and functional perspectives","volume":"1834","author":"Chen","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.autrev.2017.07.019_bb0200","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa052955","article-title":"Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis","volume":"354","author":"Baroni","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.07.019_bb0205","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.autrev.2007.02.020","article-title":"Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets","volume":"7","author":"Gabrielli","year":"2007","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2017.07.019_bb0210","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/art.24381","article-title":"Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis","volume":"60","author":"Classen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.019_bb0215","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/art.24365","article-title":"Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera","volume":"60","author":"Loizos","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.019_bb0220","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/art.24364","article-title":"Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology","volume":"60","author":"Dragun","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.019_bb0225","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/art.39125","article-title":"Epitope specificity determines pathogenicity and detectability of anti-platelet-derived growth factor receptor alpha autoantibodies in systemic sclerosis","volume":"67","author":"Moroncini","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.019_bb0230","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/art.39728","article-title":"Induction of scleroderma fibrosis in skin-humanized mice by administration of anti-platelet-derived growth factor receptor agonistic autoantibodies","volume":"68","author":"Luchetti","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"2 Suppl 71","key":"10.1016\/j.autrev.2017.07.019_bb0235","first-page":"S17","article-title":"Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis","volume":"30","author":"Daoussis","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"4 Suppl 91","key":"10.1016\/j.autrev.2017.07.019_bb0240","first-page":"S160","article-title":"Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab","volume":"33","author":"Fraticelli","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.019_bb0245","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.4049\/jimmunol.175.7.4555","article-title":"Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-beta pathway to recapitulate the \u201cscleroderma phenotype\u201d","volume":"175","author":"Zhou","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2017.07.019_bb0250","doi-asserted-by":"crossref","first-page":"R74","DOI":"10.1186\/ar3336","article-title":"Identification of new autoantibody specificities directed at proteins involved in the transforming growth factor beta pathway in patients with systemic sclerosis","volume":"13","author":"Bussone","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.07.019_bb0255","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00403-009-0996-9","article-title":"Autoantibody against one of the antioxidant repair enzymes, methionine sulfoxide reductase A, in systemic sclerosis: association with pulmonary fibrosis and vascular damage","volume":"302","author":"Ogawa","year":"2010","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.019_bb0260","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.rdc.2015.04.007","article-title":"Systemic sclerosis: gastrointestinal disease and its management","volume":"41","author":"Gyger","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2017.07.019_bb0265","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-94-007-4549-0_19","article-title":"Antiendothelial cells antibodies in patients with systemic sclerosis in relation to pulmonary hypertension and lung fibrosis","volume":"756","author":"Lewandowska","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.autrev.2017.07.019_bb0270","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/08916934.2013.812080","article-title":"Functional implications of IgG anti-endothelial cell antibodies in pulmonary arterial hypertension","volume":"46","author":"Arends","year":"2013","journal-title":"Autoimmunity"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.019_bb0275","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/ar4503","article-title":"Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients","volume":"16","author":"Gunther","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.07.019_bb0280","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/ard.2010.135772","article-title":"Involvement of functional autoantibodies against vascular receptors in systemic sclerosis","volume":"70","author":"Riemekasten","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.019_bb0285","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1164\/rccm.201403-0442OC","article-title":"Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis","volume":"190","author":"Becker","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2017.07.019_bb0290","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3899\/jrheum.150061","article-title":"Autoantibodies against endothelin 1 type a receptor are strong predictors of digital ulcers in systemic sclerosis","volume":"42","author":"Avouac","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.019_bb0295","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.vph.2013.05.002","article-title":"Agonistic anti-ICAM-1 antibodies in scleroderma: activation of endothelial pro-inflammatory cascades","volume":"59","author":"Wolf","year":"2013","journal-title":"Vascul Pharmacol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217302021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217302021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T16:59:23Z","timestamp":1535561963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997217302021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1568997217302021"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2017.07.019","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of anti-receptor autoantibodies in pathophysiology of scleroderma","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2017.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}